CJC 1295 with DAC CD5 5mg*10vials

CJC 1295 CD5 (5mg*10 vials) is an upgraded intermediate- to long-acting growth hormone-releasing hormone (GHRH) analog research peptide, a mid-range upgrade from the basic CD2 version in the CD series. CD5 retains the classic DAC (drug affinity complex) albumin-binding modification technology, exhibiting a stable 6-8 day ultra-long circulating half-life, effectively resisting DPP-IV enzyme degradation and rapid renal clearance. CD5 has optimized molecular activity and is available in a standard 5mg concentration, demonstrating significantly higher GH/IGF-1 axis activation efficiency than CD2, combining stable long-acting properties with significant experimental phenotypic differentiation capabilities. It is ideal for medium-dose gradient efficacy studies, moderate-intensity body composition remodeling, validation of anti-aging endocrine mechanisms, and long-term, highly stable metabolic intervention experiments. As a core upgraded ingredient in mainstream long-acting growth hormone peptide series, CJC 1295 DAC CD5 covers most routine and advanced preclinical endocrine research scenarios.

Product Functions and Research Value

In systematic laboratory studies, CJC 1295 DAC CD5 stably and potently stimulates the synthesis and secretion of pituitary growth hormone, achieving sustained high-amplitude upregulation of systemic IGF-1 levels. Thanks to its unique long-acting DAC modification technology, it provides sustained physiological endocrine stimulation for several days, avoiding the drastic fluctuations in short-acting peptide hormone levels. Compared to the mild, low-dose CD2 version, CD5 exhibits stronger anabolic and lipolytic activity, producing more intuitive and significant experimental results. Its core research value encompasses moderately promoting lean muscle tissue proliferation and repair, effectively regulating systemic fat metabolism, deeply promoting collagen synthesis and skin connective tissue remodeling, and conducting mid-term intervention studies on age-related endocrine atrophy and metabolic decline. CD5 demonstrates balanced efficacy and excellent model tolerability, effectively avoiding low-dose phenotypic ambiguity and high-dose physiological stress, providing high-quality, highly discriminative, and reproducible core data for studies on the mechanisms of the medium-to-high threshold GH/IGF-1 axis.

Core Product Advantages

1. CD5 Intermediate Enhancement Iteration: An intermediate-level upgrade based on CD2, optimizing molecular activity and target binding efficiency. While maintaining ultra-stable long-acting properties, it significantly enhances endocrine activation intensity, filling the gap between basic low-dose and extremely high-dose studies.

2. Stable DAC Long-Acting Core Mechanism: Mature albumin-binding modification technology ensures its strong anti-enzymatic degradation ability, maintaining an ultra-long half-life of 6-8 days. Supports low-frequency dosing and long-term continuous intervention, greatly improving the efficiency of chronic endocrine modeling.

3. 5mg Standard Balanced Concentration: The classic mainstream intermediate-potency specification in the CD series. It perfectly solves the problem of insufficient efficacy of low-dose CD2 products, taking into account experimental safety and phenotypic significance, making it the preferred specification for most routine gradient experiments and batch replication validation.

4. High-Purity Selective Endocrine Regulation: Precisely targets the GHRH-GH-IGF-1 signaling axis with high specificity. It effectively regulates anabolic metabolism and metabolism without interfering with cortisol, prolactin, and other stress hormones, ensuring the purity and reliability of experimental variables. 5. Pharmaceutical-grade process and standard packaging: Utilizing aseptic vacuum freeze-drying technology for enhanced activity locking. Each batch undergoes rigorous HPLC purity testing and comes with a complete Certificate of Account (COA). Each box contains 10 vials in integrated aseptic packaging, meeting the needs of routine laboratory research, key endocrinology projects in universities, and large-scale wholesale procurement.

CJC 1295 DAC CD5 5mg*10 vials. This product is a medium-to-long-acting growth hormone-releasing hormone (GHRH) analog research peptide, a core iteration of the CD series, and a comprehensive upgrade of the basic CD2 version. This product employs classic and mature DAC drug affinity complex modification technology, stably binding to serum albumin, effectively resisting DPP-IV enzyme degradation and renal clearance, maintaining an ultra-long in vivo half-life of 6-8 days, demonstrating excellent long-term stability. Through molecular activity optimization and upgrades, combined with a standard 5mg medium-acting concentration, it enhances the activation intensity and regulatory capacity of the GH/IGF-1 endocrine axis.